SCHEMBL27167464

SCHEMBL27167464

COc1cc2nc(N3CCOCC3)[nH]c(=O)c2cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HPGD P15428 2/20 0.52
▸ PDE10A Q9Y233 1/20 0.51
▸ APP P05067 1/20 0.51
▸ BCHE P06276 1/20 0.51
▸ ACHE P22303 1/20 0.51
▸ MAPT P10636 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ EHMT2 Q96KQ7 2/20 0.46
▸ EHMT1 Q9H9B1 2/20 0.46
▸ MAP2K7 O14733 1/20 0.46
▸ HTR3A P46098 1/20 0.45
▸ HRH4 Q9H3N8 1/20 0.45
▸ PIK3CD O00329 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30054892 1.00 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL4985818 0.81 SMN1; SMN2 (0.44) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL20422066 0.81 MAPT (0.52) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL5880447 0.81 PDE10A (0.52) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL5880628 0.81 ALDH1A1 (0.48) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL20422061 0.80 MAPT (0.45) SMN1; SMN2ALDH1A1HPGDMAPTKDM4E
SCHEMBL5880430 0.79 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL6394632 0.78 ALDH1A1 (0.42) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL5880545 0.77 ALDH1A1 (0.49) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL5880470 0.77 ALDH1A1 (0.46) SMN1; SMN2MEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262822-A1 WDR5 INHIBITORS AND MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-08-08 — — US disclosed
EP-4334305-A1 WDR5 INHIBITORS AND MODULATORS Vanderbilt University (US) 2024-03-13 — — EP disclosed
WO-2022236101-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY (US) 2022-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262822-A1 WDR5 INHIBITORS AND MODULATORS WDR5, WDR1, WDR3 SMN1; SMN2 2023/4885MEN1 2330/4885KMT2A 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback